Skip to main content

Zingo FDA Approval History

FDA Approved: Yes (First approved August 16, 2007)
Brand name: Zingo
Generic name: lidocaine hydrochloride monohydrate
Dosage form: Dermal PowderJect
Company: Anesiva, Inc.
Treatment for: Local Anesthesia

Zingo (lidocaine hydrochloride monohydrate) is a needle-free, local anesthetic intradermal injection system, which provides rapid, topical, local analgesia to reduce the pain associated with venous access procedures, such as IV insertions or blood draws.

Development timeline for Zingo

DateArticle
Jan  9, 2009Approval Anesiva Announces FDA Approval of sNDA to Expand Zingo Indication to Include Adults
Aug 17, 2007Approval Anesiva Receives FDA Approval for Zingo, a New, Innovative Productto Reduce Pain Associated with Needle Insertion Procedures inChildren
Apr 10, 2007Endo Comments on Notices Received From Anesiva Regarding Zingo
Feb  7, 2007Anesiva Announces FDA Acceptance for Filing of Zingo New Drug Application to Reduce Pain Associated With Needle Insertion Procedures in Children
Nov 27, 2006Anesiva Announces Filing of New Drug Application for Zingo to Reduce Pain Associated with Needle Insertion Procedures in Children

See also

Zingo (lidocaine hydrochloride monohydrate) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer